INmune Bio (INMB) News Today $2.56 -0.17 (-6.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.60 +0.04 (+1.56%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period INmune Bio options imply 14.9% move in share price post-earningsAugust 1 at 4:44 AM | msn.comINmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7thJuly 31 at 7:00 AM | globenewswire.comINmune Bio (INMB) to Release Quarterly Earnings on ThursdayJuly 31 at 3:55 AM | marketbeat.comINmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International ConferenceJuly 29, 2025 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Consensus PT from AnalystsJuly 29, 2025 | americanbankingnews.com2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...July 28, 2025 | benzinga.comINmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 26, 2025 | marketbeat.comINmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer'sJuly 4, 2025 | seekingalpha.com'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On MondayJuly 4, 2025 | benzinga.comINmune Bio: Hold Rating Based On Path Forward Of XPro In Subset Of AD PatientsJuly 3, 2025 | seekingalpha.comMaxim Group Cuts INmune Bio (NASDAQ:INMB) Price Target to $8.00July 2, 2025 | marketbeat.comINmune slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug missJuly 2, 2025 | au.finance.yahoo.comScotiabank Downgrades INmune Bio (INMB)July 2, 2025 | msn.comINmune Bio: What's Left For InvestorsJuly 2, 2025 | seekingalpha.comINmune Bio (NASDAQ:INMB) Rating Lowered to Hold at Raymond James FinancialJuly 2, 2025 | marketbeat.comINmune Bio (NASDAQ:INMB) Lowered to "Neutral" Rating by BTIG ResearchJuly 1, 2025 | marketbeat.comINmune Bio (NASDAQ:INMB) Lowered to Sector Underperform Rating by ScotiabankJuly 1, 2025 | marketbeat.comINmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial resultsJuly 1, 2025 | finance.yahoo.comINmune Bio fails to meet main goal in Alzheimer's treatment studyJuly 1, 2025 | msn.comINmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumbleJuly 1, 2025 | finance.yahoo.comINmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug TrialJuly 1, 2025 | msn.comINmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record lowJuly 1, 2025 | msn.comINmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 30, 2025 | globenewswire.comINmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trialJune 30, 2025 | proactiveinvestors.comINmune Bio's Alzheimer's drug fails to meet main goal in mid-stage studyJune 30, 2025 | reuters.comINmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's DiseaseJune 30, 2025 | globenewswire.comINmune Bio's US$24m Market Cap Fall Books Insider LossesJune 28, 2025 | finance.yahoo.comINmune Bio Inc. (INMB) Stock Price Today - WSJJune 28, 2025 | wsj.comINmune Bio Stock Price, Quotes and Forecasts | NASDAQ:INMB - BenzingaJune 28, 2025 | benzinga.comINmune Bio Stock (NASDAQ:INMB), Insider Trading ActivityJune 27, 2025 | benzinga.comINmune Bio Shares Pare Back Gains Following Direct OfferingJune 27, 2025 | marketwatch.comINmune Bio: Finding Pay Dirt In Alzheimer's?June 27, 2025 | seekingalpha.comINmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 27, 2025 | globenewswire.comINmune Bio Stock Soars Friday On Alzheimer's Treatment HopesJune 27, 2025 | benzinga.comINMB - INmune Bio Inc News - MorningstarJune 27, 2025 | morningstar.comMINmune Bio Climbs on Plan to Report Alzheimer's Study Data MondayJune 26, 2025 | marketwatch.comLas acciones de INmune Bio se disparan antes de la publicación de datos sobre AlzheimerJune 26, 2025 | es.investing.comINmune Bio put volume heavy and directionally bearishJune 26, 2025 | msn.comINmune Bio stock soars ahead of Alzheimer’s trial data releaseJune 26, 2025 | za.investing.comINmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30thJune 26, 2025 | finance.yahoo.comINmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30thJune 26, 2025 | globenewswire.comINmune Bio Target of Unusually High Options Trading (NASDAQ:INMB)June 20, 2025 | marketbeat.comINmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative OpportunityJune 16, 2025 | seekingalpha.comINmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in MiceJune 12, 2025 | nasdaq.comINmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LPJune 11, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB)June 4, 2025 | marketbeat.comINmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big OpportunityMay 15, 2025 | seekingalpha.comINmune Bio, Inc. (INMB) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comINmune Bio appoints new accounting firmMay 9, 2025 | investing.comINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.de Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Media Mentions By Week INMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼0.240.63▲Average Medical News Sentiment INMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼63▲INMB Articles Average Week Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Annexon News Today Lifecore Biomedical News Today Zhengye Biotechnology News Today DBV Technologies News Today Aurora Cannabis News Today Monopar Therapeutics News Today Prima BioMed News Today Inozyme Pharma News Today Cardiff Oncology News Today Editas Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
